12-10-2013, 07:28 AM
|
#1
|
|
Senior Member
Join Date: Aug 2006
Posts: 3,380
|
ultra-deep targeted sequencing for personalized bc care
http://breast-cancer-research.com/co...df/bcr3584.pdf
At page 13:
Quote:
|
Looking at somatic mutations and amplification, we would have proposed the use of Trastuzumab for 7 patients based on ERBB2 status. Notably, for one of them the ERBB2 gene is not amplified but carried an activating mutation, which would have been missed through standard Her2 testing.
|
Hopeful
|
|
|